Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 23.7% in February

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 1,060,000 shares, a decrease of 23.7% from the February 13th total of 1,390,000 shares. Approximately 13.5% of the shares of the company are sold short. Based on an average trading volume of 92,200 shares, the short-interest ratio is presently 11.5 days.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI traded down $0.42 during trading on Monday, hitting $6.33. The company’s stock had a trading volume of 37,339 shares, compared to its average volume of 89,717. The company has a 50-day moving average of $9.17 and a 200-day moving average of $10.87. Karyopharm Therapeutics has a 12 month low of $5.90 and a 12 month high of $24.75. The firm has a market cap of $53.26 million, a price-to-earnings ratio of -6.18 and a beta of 0.11.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, topping the consensus estimate of ($3.90) by $0.30. The business had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. As a group, research analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Analysts Set New Price Targets

KPTI has been the topic of several research analyst reports. StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. HC Wainwright upped their target price on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Robert W. Baird lowered their target price on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $57.50.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its holdings in Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after acquiring an additional 36,922 shares in the last quarter. Silverarc Capital Management LLC grew its holdings in Karyopharm Therapeutics by 6.7% during the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock valued at $403,000 after buying an additional 37,524 shares in the last quarter. Velan Capital Investment Management LP purchased a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $27,000. Two Sigma Advisers LP grew its holdings in Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after buying an additional 45,400 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $31,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).